Answer
Tagrisso (osimertinib mesylate) should not be used during pregnancy unless the woman’s clinical condition requires osimertinib treatment, because human pregnancy data are absent or limited, animal studies show reproductive toxicity, and its mechanism and preclinical data indicate potential foetal harm.
Sources for this answer
- Tagrisso 40 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 33Document updated
Sources checked